Cenzo Congiu

ORCID: 0000-0003-2600-4221
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Synthesis and biological activity
  • Synthesis and Characterization of Heterocyclic Compounds
  • Synthesis of heterocyclic compounds
  • Synthesis and Reactions of Organic Compounds
  • Synthesis and Biological Evaluation
  • Synthesis and Reactivity of Heterocycles
  • Quinazolinone synthesis and applications
  • Synthesis and Reactivity of Sulfur-Containing Compounds
  • Fluorine in Organic Chemistry
  • Click Chemistry and Applications
  • Cancer therapeutics and mechanisms
  • Cannabis and Cannabinoid Research
  • Synthesis and Characterization of Pyrroles
  • Chemical synthesis and pharmacological studies
  • Synthesis and Catalytic Reactions
  • Enzyme function and inhibition
  • Inflammatory mediators and NSAID effects
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • HIV/AIDS drug development and treatment
  • Receptor Mechanisms and Signaling
  • Neuropeptides and Animal Physiology
  • Multiple Sclerosis Research Studies
  • Cyclopropane Reaction Mechanisms
  • Synthesis of Organic Compounds
  • Hypothalamic control of reproductive hormones

University of Cagliari
2006-2015

University of Brescia
2015

University of Ferrara
2006-2015

Sapienza University of Rome
2014-2015

Stanford University
2015

San Raffaele University of Rome
2015

Universitat Autònoma de Barcelona
2014-2015

Istituto Superiore di Sanità
2014-2015

Pharmac
2014

Komatsu (Japan)
2006

10.1016/s0223-5234(00)00149-5 article EN European Journal of Medicinal Chemistry 2000-05-01

To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, CNS autoimmune demyelinating disease.We investigated expression PK2 mice with experimental encephalomyelitis (EAE), animal model sclerosis (MS), and patients relapsing-remitting MS. We evaluated effects on EAE development T-cell response against myelin by blocking vivo receptor antagonists. treated cells activated antigen to explore...

10.1212/nxi.0000000000000095 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2015-04-10

The synthesis and anticancer activity of new compounds designed on the anthranilic acid scaffold are reported. antiproliferative was assayed by National Cancer Institute in established vitro vivo experimental models. Structural variations based flufenamic motif afforded a series (hetero)aryl esters N-(2-(trifluoromethyl)pyridin-4-yl)anthranilic acid, which showed growth inhibitory properties against human tumor cell lines nanomolar to low micromolar concentrations. pyridinyl ester 25...

10.1021/jm050711d article EN Journal of Medicinal Chemistry 2005-11-15

A dual-action cyclooxygenase (COX)-fatty acid amide hydrolase (FAAH) inhibitor may have therapeutic usefulness as an analgesic, but a key issue is finding the right balance of inhibitory effects. This can be done by design compounds exhibiting different FAAH/COX-inhibitory potencies. In present study, eight ibuprofen analogues were investigated. Ibuprofen (1), 2-(4-Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide (9) and...

10.3109/14756366.2011.643304 article EN Journal of Enzyme Inhibition and Medicinal Chemistry 2012-01-06

PPARγ-deficient mice die at E9.5 due to placental abnormalities. The mechanism by which this occurs is unknown. We demonstrated that the new endocrine factor EG-VEGF controls same processes as those described for PPARγ, suggesting potential regulation of PPARγ. exerts its functions via prokineticin receptor 1 (PROKR1) and 2 (PROKR2). This study sought investigate whether mediates part PPARγ effects on development. Three approaches were used: 1) in vitro, using human primary isolated...

10.1152/ajpendo.00093.2015 article EN AJP Endocrinology and Metabolism 2015-06-17

Fatty acid amide hydrolase (FAAH) is the key hydrolytic enzyme for endogenous cannabinoid receptor ligand anandamide. The synthesis and evaluation their FAAH inhibitory activities of a series 18 paracetamol esters are described. Structure-activity relationship studies indicated that ester (33) with 2-(4-(2-(trifluoromethyl)pyridin-4-ylamino)phenyl)acetic substituent was most potent analogue in this series. compound inhibited activity competitive manner K(i) value 0.16 microM. also able to...

10.1021/jm901891p article EN Journal of Medicinal Chemistry 2010-02-09
Coming Soon ...